glp 1 alzheimers Frontiers Novo Nordisk justifies reasoning behind

wrote the first draft

The American Diabetes Association (ADA) guidelines updated in 2023 recommend GLP-1 receptor agonists as a preferred treatment option for many patients with type 2 diabetes, particularly those with or at high risk for cardiovascular disease or kidney disease

The GLP-1 (Glucagon-Like Peptide-1) Receptor Agonist Market is undergoing a paradigm shift, transforming from a niche therapeutic class primarily used in type 2 diabetes management to a multi-billion-dollar market at the heart of the global obesity epidemic

Statements Data availability statement The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author

This is far more significant weight loss than reported in prior studies which may explain the larger effect on her lymphedema